Deutsche Bank AG Trims Stock Holdings in Penumbra, Inc. (NYSE:PEN)

Deutsche Bank AG lowered its stake in Penumbra, Inc. (NYSE:PEN - Free Report) by 22.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,223 shares of the company's stock after selling 2,384 shares during the quarter. Deutsche Bank AG's holdings in Penumbra were worth $1,953,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Penumbra during the 4th quarter worth about $573,000. E. Ohman J or Asset Management AB raised its holdings in Penumbra by 10.4% during the fourth quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company's stock worth $5,061,000 after purchasing an additional 2,000 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Penumbra by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company's stock worth $64,493,000 after purchasing an additional 3,807 shares during the period. Washington Capital Management Inc. acquired a new stake in Penumbra in the fourth quarter worth approximately $226,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in Penumbra by 39.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 299,397 shares of the company's stock valued at $71,831,000 after purchasing an additional 85,284 shares in the last quarter. Institutional investors own 88.88% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. UBS Group reissued a "buy" rating and issued a $330.00 price objective (up previously from $320.00) on shares of Penumbra in a research note on Thursday, April 24th. Robert W. Baird upped their price target on shares of Penumbra from $316.00 to $325.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Morgan Stanley lifted their price objective on shares of Penumbra from $240.00 to $260.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 19th. Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a report on Wednesday, February 19th. Finally, JPMorgan Chase & Co. raised their target price on shares of Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Penumbra has a consensus rating of "Moderate Buy" and a consensus price target of $302.40.

Insider Buying and Selling

In related news, Director Thomas Wilder sold 360 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $264.58, for a total transaction of $95,248.80. Following the completion of the transaction, the director now owns 4,533 shares in the company, valued at $1,199,341.14. This trade represents a 7.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Johanna Roberts sold 600 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $269.11, for a total transaction of $161,466.00. Following the completion of the sale, the executive vice president now owns 66,353 shares of the company's stock, valued at $17,856,255.83. The trade was a 0.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 176,696 shares of company stock worth $50,207,745 in the last quarter. 5.00% of the stock is currently owned by company insiders.

Penumbra Stock Up 0.3%

Penumbra stock traded up $0.77 during mid-day trading on Thursday, hitting $265.06. The company's stock had a trading volume of 426,101 shares, compared to its average volume of 446,263. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The company has a market cap of $10.26 billion, a PE ratio of 779.59, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The firm's 50 day moving average is $278.51 and its 200 day moving average is $265.81.

Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The business had revenue of $324.14 million during the quarter, compared to analyst estimates of $315.72 million. During the same period in the prior year, the firm earned $0.41 earnings per share. The firm's revenue was up 16.3% compared to the same quarter last year. On average, analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.